[1] |
Ananthakrishnan, R., Green, S., Previtali, A., Liu, R., Li, D., & LaValley, M. (2021). Critical review of oncology clinical trial design under non‐proportional hazards. Critical Reviews in Oncology/Hematology, 162, 103350. |
[2] |
Borghaei, H., Paz‐Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., … Brahmer, J. R. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small‐cell lung cancer. New England Journal of Medicine, 373(17), 1627-1639. |
[3] |
Brendel, M., Janssen, A., Mayer, C.‐D., … Pauly, M. (2014). Weighted logrank permutation tests for randomly right censored life science data. Scandinavian Journal of Statistics, 41(3), 742-761. · Zbl 1309.62164 |
[4] |
Breslow, N. E., Edler, L., & Berger, J. (1984). A two‐sample censored‐data rank test for acceleration. Biometrics, 40, 1049-1062. · Zbl 0562.62042 |
[5] |
Cheng, H., & He, J. (2021). A maximum weighted logrank test in detecting crossing hazards. arXiv. https://doi.org/10.48550/arXiv.2110.03833 · doi:10.48550/arXiv.2110.03833 |
[6] |
Ditzhaus, M., & Friedrich, S. (2020). More powerful logrank permutation tests for two‐sample survival data. Journal of Statistical Computation and Simulation, 90, 2209-2227. · Zbl 07480170 |
[7] |
Freedman, L. S. (1982). Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine, 1(2), 121-129. |
[8] |
Garès, V., Andrieu, S., Dupuy, J.‐F., & Savy, N. (2015). An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials. Statistics in Medicine, 34(4), 541-557. |
[9] |
Hasegawa, T. (2014). Sample size determination for the weighted log‐rank test with the Fleming-Harrington class of weights in cancer vaccine studies. Pharmaceutical Statistics, 13(2), 128-135. |
[10] |
Hasegawa, T. (2016). Group sequential monitoring based on the weighted log‐rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies. Pharmaceutical Statistics, 15(5), 412-419. |
[11] |
Jachno, K., Heritier, S., & Wolfe, R. (2019). Are non‐constant rates and non‐proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice. BMC Medical Research Methodology, 19(1), 103. |
[12] |
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., & Schellhammer, P. F. (2010). Sipuleucel‐t immunotherapy for castration‐resistant prostate cancer. New England Journal of Medicine, 363(5), 411-422. |
[13] |
Kosorok, M. R., & Lin, C.‐Y. (1999). The versatility of function‐indexed weighted log‐rank statistics. Journal of the American Statistical Association, 94(445), 320-332. · Zbl 1072.62575 |
[14] |
Lakatos, E. (1986). Sample size determination in clinical trials with time‐dependent rates of losses and noncompliance. Controlled Clinical Trials, 7(3), 189-199. |
[15] |
Lakatos, E. (1988). Sample sizes based on the log‐rank statistic in complex clinical trials. Biometrics, 44, 229-241. · Zbl 0707.62262 |
[16] |
Lee, J. W. (1996). Some versatile tests based on the simultaneous use of weighted log‐rank statistics. Biometrics, 52, 721-725. · Zbl 0875.62169 |
[17] |
Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T.‐T., & Iacona, R. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis. Statistics in Biopharmaceutical Research, 12(2), 187-198. |
[18] |
Mok, T., Kim, D., Wu, Y., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Wilner, K., Blackhall, F., & Solomon, B. J. (2017). Overall survival (OS) for first‐line Crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014. Annals of Oncology, 28, 637. |
[19] |
Phadnis, M. A., & Mayo, M. S. (2021). Sample size calculation for two‐arm trials with time‐to‐event endpoint for nonproportional hazards using the concept of relative time when inference is built on comparing Weibull distributions. Biometrical Journal, 63(7), 1406-1433. · Zbl 1523.62182 |
[20] |
Phadnis, M. A., Wetmore, J. B., & Mayo, M. S. (2017). A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution. Statistics in Medicine, 36(26), 4121-4140. |
[21] |
Roychoudhury, S., Anderson, K. M., Ye, J., & Mukhopadhyay, P. (2021). Robust design and analysis of clinical trials with nonproportional hazards: A straw man guidance from a cross‐pharma working group. Statistics in Biopharmaceutical Research. Advanced online publication. https://doi.org/10.1080/19466315.2021.1874507 · doi:10.1080/19466315.2021.1874507 |
[22] |
Royston, P., & Parmar, M. K. (2013). Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time‐to‐event outcome. BMC Medical Research Methodology, 13(1), 1-15. |
[23] |
Schoenfeld, D. (1981). The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika, 68(1), 316-319. |
[24] |
Wang, L., Luo, X., & Zheng, C. (2021). A simulation‐free group sequential design with Max‐combo tests in the presence of non‐proportional hazards. Pharmaceutical Statistics, 20, 879-897. |
[25] |
Xiong, X., & Wu, J. (2017). A novel sample size formula for the weighted log‐rank test under the proportional hazards cure model. Pharmaceutical Statistics, 16(1), 87-94. |
[26] |
Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in Medicine, 36(4), 592-605. |
[27] |
Zhang, D., & Quan, H. (2009). Power and sample size calculation for log‐rank test with a time lag in treatment effect. Statistics in Medicine, 28(5), 864-879. |